Chelsea Therapeutics International Ltd. (CHTP)
-NasdaqCM 1.84 
0.06(3.16%) May 24, 4:00PM EDT
| Prev Close: | 1.90 |
|---|
| Open: | 1.88 |
|---|
| Bid: | 1.65 x 100 |
|---|
| Ask: | 2.11 x 400 |
|---|
| 1y Target Est: | 4.63 |
|---|
| Beta: | 1.4 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 1.83 - 1.90 |
|---|
| 52wk Range: | 0.70 - 2.17 |
|---|
| Volume: | 720,277 |
|---|
| Avg Vol (3m): | 941,212 |
|---|
| Market Cap: | 123.44M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Chelsea Therapeutics to Present at the 38th Annual Deutsche Bank Health Care ConferenceGlobeNewswire(Wed May 22)
- Call buying in Chelsea TherapeuticsoptionMONSTER(Wed May 22)
- Today’s Research on HSP, ALKS, CLSN, THRX, and CHTPAccesswire(Mon May 13)
- CHELSEA THERAPEUTICS INTERNATIONAL, LTD. FinancialsEDGAR Online Financials(Tue May 7)
- Chelsea Therapeutics Reports First Quarter 2013 Financial ResultsGlobeNewswire(Wed May 1)
- CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed May 1)
- Chelsea Therapeutics to Present at the 12th Annual Needham Healthcare ConferenceGlobeNewswire(Wed Apr 24)
- Lead Counsel in Securities Class Action Against Chelsea Therapeutics International Ltd. Announces Court HearingPR Newswire(Fri Apr 19)
- CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Files SEC form 8-K, Change in Directors or Principal Officers, Financial StaEDGAR Online(Fri Apr 19)
- Is Chelsea Therapeutics A Buy After Skyrocketing Up Over 150%?at Seeking Alpha(Mon Apr 8)
- Why Starbucks is a Screaming Buy and 3 Other Hot Stocksat Wall St. Cheat Sheet(Wed Mar 27)
- Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Hereat Seeking Alpha(Tue Mar 26)
- 4 Stocks Under $10 Making Big Movesat TheStreet(Thu Mar 21)
- Chelsea Therapeutics Announces Presentation of Northera(TM) (droxidopa) Study 306 Data at the American Academy of Neurology Annual MeetingGlobeNewswire(Tue Mar 19)
- Avoid This Biotech Stockat Motley Fool(Fri Mar 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.30 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products.
View More